Using MR, a genetically instrumented SD increase in pyruvate increased the odds of PCA by 1.29 (1.03, 1.62; p=0.027).
Abstract Background
Feasibility trials are preliminary trials that assess the viability and acceptability of intervention studies and the effects of the intervention on intermediate endpoints. Due to their short duration, they are unable to establish the effects of the intervention on long-term clinical outcomes. We propose a novel method that could transform the interpretation of feasibility trials using modified two-stage randomisation analyses.
Methods
In this two-stage process, we explored the effects of a 6-month feasibility factorial randomised controlled trial (RCT) of lycopene and green tea dietary interventions (ProDiet) on 159 serum metabolic traits in 133 men with raised PSA levels but prostate cancer (PCA) free. In the first stage, we conducted an intention-to-treat analysis, using linear regression to examine the effects of the interventions on metabolic traits, compared to the placebo group and instrumental variable analysis to assess the causal effect of the intervention on the outcomes. In the second stage, we used a twosample Mendelian Randomization (MR) approach to assess the causal effect of metabolic traits altered by the interventions, on PCA risk, using summary statistics data from an international PCA consortium of 44,825 cancer cases and 27,904 controls.
Results
The systemic effects of lycopene and green tea supplementation on serum metabolic profile were comparable to the effects of the respective dietary advice interventions (R2= 0.65 and 0.76 for lycopene and green tea respectively). Metabolites which were altered in response to lycopene supplementation were acetate (standard deviation difference versus placebo (β)): 0.69; 95% CI= 0.24, 1.15; p=0.003), valine (β: -0.62; -1.03, -0.02; p=0.004), pyruvate (β: -0.56; -0.95, -0.16; p=0.006), and docosahexaenoic acid (β: -0.50; -085, -0.14; p=0.006). The instrumental variable analysis showed there was no evidence that green tea altered the metabolome, but lycopene was associated with an increase in acetate (β=2.13; p=0.006) and decreases in pyruvate (β=-1.90; p=0.009), valine (β=-1.79; p=0.023), diacylglycerol (β=-1.81; p=0.026), alanine (β=-1.55; p=0.015) and DHA (p=0.097), where the regression coefficient represents the standard deviation (SD) difference in metabolite measures per unit change in lycopene (µmol/L) or EGCG (nM).
Introduction
Feasibility studies are small-scale studies, including those with a randomised controlled trial (RCT) design, which aim to assess whether and how a novel intervention can be practically tested in a definitive RCT and ultimately implemented in a clinical setting (2) . Feasibility trials are not powered to evaluate the effects of the intervention on clinical outcomes and participants are not typically followed-up for enough time to assess long-term outcomes (2) .
Nonetheless, intermediate endpoints on the causal pathway to clinical outcomes may be measured in feasibility studies in an attempt to predict the clinical and long-term impact of a novel intervention. In this paper we propose a method of robustly predicting the effects of novel interventions on long-term clinical outcomes using data on intermediate endpoints from small feasibility studies.
Box 1. List of Definitions

Box 2. Key Messages
Challenges of feasibility trials
Feasibility trials aim to assess whether an intervention can be delivered, and a trial performed, in a particular setting. They are typically small in scale and are conducted to Feasibility studies are small scale studies that aim to assess whether a large study can be delivered.
Mendelian Randomisation (MR)
is an approach which uses genetic variants reliably associated with a potentially modifiable exposure to assess whether associations between modifiable risk factors and disease are likely to be causal.
Genetic variant is an alteration in the DNA sequence, such as a single nucleotide polymorphism (SNP).
Intermediate endpoint is a measurable variable, often a biomarker, which may be on the causal pathway to clinical outcomes.
Biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease (1).
• Feasibility studies are small scale studies that aim to assess whether a study can be practically implemented and to inform the design of larger trials, but due to low statistical power and short duration of follow-up, feasibility studies cannot assess the clinical outcomes of interest, such as disease risk or progression.
• Mendelian Randomisation is an approach which uses genetic variants reliably associated with a potentially modifiable exposure to assess whether associations between modifiable risk factors and disease are likely to be causal 
Two-step randomisation in feasibility trials
In a randomised controlled trial (RCT) participants are randomly assigned to multiple groups.
Typically, there is an "exposed" group in which participants are randomised to receive an intervention or treatment, and an "unexposed" group in which participants are randomised to not receive the intervention or treatment, commonly referred to as the placebo or control group. In the most robust analysis of RCTs, intention to treat (ITT), the aim is to compare differences between the intervention groups in terms of predefined outcomes (4) . ITT however, does not reflect the actual causal effect of the intervention on the outcome, as it does not take into account participant habits (eg non-compliers who do not fully adhere to the intervention). We therefore need to perform an instrumental variable (IV) analysis, where the assignment to treatment serves as 'instrument' and allows to estimate the causal effect of the intervention on the outcomes.
Mendelian Randomisation (MR) is an analytical technique that uses germline genetic variants
robustly associated with an exposure of interest in a natural experiment ("nature's randomised controlled trial") to determine the causal effect of a potentially modifiable exposure on an outcome (5) . At conception, germline variants that are associated with a particular trait are randomly distributed with respect to other unrelated traits and environmental factors, akin to random assignment of exposure to treatment or intervention in a conventional RCT (2, 5, 6) . Although there are many considerations that should be taken into account when using MR, we can construct an experiment in which people are naturally randomly allocated to a particular exposure based on single nucleotide polymorphisms (SNPs) associated with the exposure of interest (7) . Similar to a traditional RCT, and in its simplest form, MR based on one SNP yields an "exposed group" of individuals with a particular genetic variant (allele) which can be compared with an "unexposed group" of individuals without that allele to determine if the outcome occurs more or less frequently in the exposed group compared to the unexposed one. By comparing the outcomes by groups we can establish whether the relationship between exposure and outcome of interest is likely to be causal (8) . DNA, although itself unmodifiable, operates through modifiable pathways. MR exploits this to identify modifiable exposures that can be used for disease prevention and therapeutic strategies.
We propose integrating MR into feasibility trials in a two-step process (Figure 2) . In the first step, ITT and IV analysis are conducted to establish the effects of the novel intervention on intermediate endpoints. Those intermediates altered by the intervention are then investigated further in the second step of the process, an MR analysis. The second step requires the establishment of SNPs that are robustly associated with the intermediates of interest and which can act as genetic instruments for these intermediates. Such genetic instruments are usually identified from previously conducted, large-scale and replicated genome-wide association studies (GWAS). After establishing the SNPs that will be used as instruments, those SNPs are integrated with data from large GWAS consortia investigating the clinical outcome of interest. This second step assesses the causal effect of the intermediates on the outcomes of interest, such as disease risk or progression in a formal MR study.
By considering the results from the two steps, it is possible to predict the potential impact of the novel intervention on long-term clinical outcomes, as well as potential adverse effects, via the intermediates. 
The ProDiet factorial feasibility RCT (10)
The ProDiet study was approved by the UK Healthcare Research Authority Trent Multicentre
Research Ethics Committee (08/H0405/61), conducted according to Declaration of Helsinki, 1964 and the trial number is ISCTRN 95931417 (10) .The study assessed the feasibility and acceptability of dietary modification in men at increased risk of prostate cancer, with a prostate specific antigen (PSA) level of 2.0-2.95 ng/mL or 3.0-19.95 ng/mL and a negative prostate biopsy (10) . Participants were randomised using a 3x3 factorial design, to both a daily green tea (drink at least 3 cups of green tea per day (unblinded) or taking capsules of the active ingredient of green tea (600 mg epigallocatechin-3-gallate (EGCG), (blinded), or placebo (blinded)) and a lycopene intervention (consuming lycopene-rich foods (unblinded) or taking lycopene capsules (15 mg, blinded) or placebo (blinded)), for 6 months (10). Primary endpoints were randomisation rates and intervention adherence (blinded assessment of lycopene and green tea catechin metabolites) at six months.
Secondary endpoints included measures of acceptability (from interviews), safety, weight, blood pressure and PSA. Of the 469 men approached, 133 (28.4%) agreed to be randomized and 132 were followed-up (99.2%) (10) . The mean serum lycopene was 1.28 (95% confidence intervals (CI) 1.09, 1.50, p = 0.003) times higher in the lycopene supplement group and 1.42 (95% CI 1.21-1.66, p<0.001) times higher in the lycopene-enriched diet group compared to placebo capsule group (10) . The median EGCG was 10.7 nM (95% CI 7.0, 32.0) higher in in the active supplement group and 20.0 nM (95% CI 0.0, 19.0) higher in the green tea drink group compared with the placebo capsule group (both p<0.001) (10) . The two-step randomisation approach in the ProDiet trial is presented in Figure   1 .
Step 1: randomised effects of lycopene and green tea on metabolite measures.
In an ITT analysis, linear regression was used to compare standardised metabolic trait measures 6months after factorial randomisation to lycopene and green tea dietary intervention arms, treating placebo as the reference category (i.e. lycopene supplement or dietary advice versus placebo and green tea supplement or dietary advice versus placebo). The magnitude of the effect of the intervention on circulating metabolic measures was expressed as a standardised mean difference and a new threshold for multiple testing (p-value) was determined using a principle component analysis (PCA) approach, to take account the correlation between metabolic traits. The findings for the ITT in step one of the analysis are presented in Table 1 and provide some evidence of a change in metabolic measures at follow-up in the lycopene intervention groups, including changes in circulating levels of valine, acetate, pyruvate, diacylglycerol and docosahexaenoic acid (DHA). There was weak evidence to suggest that levels of glycine were lower in the green-tea drinking group compared to placebo.
Using the ITT approach, it was possible to obtain evidence of a randomisation effect, i.e. evidence of a difference in metabolic trait levels between active lycopene/green tea intervention arms and placebo at follow-up, however, it did not provide an estimate of the causal effect of lycopene/EGCG dose on metabolites because some participants may not have taken the capsule/followed the dietary advice, as instructed (i.e. they were non-compliant). IV methods were therefore used to estimate the effect of the lycopene and EGCG dose on the metabolic traits. In this case, the RCT was treated as an IV, with treatment assignment as the "instrument." Using a 2-stage least squares regression approach, the intervention arm was first regressed on the follow-up serum lycopene/EGCG levels. The F-statistics and R 2 values from the first-stage regression were examined to check the instrumental variable assumption that the instrument was sufficiently associated with the exposure. Causal estimates for the instrumented effect of serum lycopene/EGCG levels on each follow-up metabolite were then obtained from the second-stage regression. Results of the IV analysis are presented in Table 2 . Again, there was no evidence that green tea altered the metabolome, but lycopene was associated with an increase in acetate (β=2.13; p=0.006) and decreases in pyruvate (β=-1.90; p=0.009), valine (β=-1.79; p=0.023), diacylglycerol (β=-1.81; p=0.026) and DHA (p=0.097). Alanine was also lower (β=-1.55; p=0.015), where the regression coefficient represents the standard deviation (SD) difference in metabolite measures per unit change in lycopene (µmol/L) or EGCG (nM). These metabolites were then carried forward to the second step of the process. 
Step 2: randomised effects of intermediate metabolites on prostate cancer risk
To appraise the causal role of altered metabolites in prostate cancer risk, SNPs robustly associated with the metabolites of interest at genome-wide significance (P<5 × 10 −8 ) for the effect of each SNP on the metabolite) were identified from a published GWAS of circulating metabolites (13) . Summary statistics were available for 17 SNPs associated with acetate (n=1 SNP), valine (n=4), pyruvate (n=2), DHA (n=4), and glycine (n=6). SNPs robustly associated with diacylglycerol were not available in the metabolite GWAS summary statistics, and therefore this metabolite could not be instrumented for MR analysis.
Summary statistics from the GWAS of metabolites were used in tandem with summary statistics for 44,825 prostate cancer cases and 27,904 controls in the PRACTICAL consortium (http://practical.icr.ac.uk/) in a two-sample MR analysis (11) . This enabled the calculation of the log odds ratio for prostate cancer per SD increase in metabolic trait levels. MR estimates for each SNP were calculated using the Wald ratio method (15, 16) , which calculates the influence of the SNPoutcome effect divided by the SNP-exposure effect. Where multiple SNPs were available, their causal effects were combined together in a fixed-effects inverse-weighted meta-analysis (IVW) approach. Results of the MR analysis (Table 3 ) provide some evidence that genetically raised pyruvate increased the odds of prostate cancer (OR per SD increase: 1.29; 95% CI: 1.03, 1.67; p=0.027). Two sensitivity analyses were conducted to assess the robustness of the results to horizontal pleiotropy, where a genetic variant modifies the outcome of interest through a pathway independent of the exposure, which can lead to biased causal estimates: a weighted median approach and MR-Egger regression (12, 17, 18 
Conclusions using Two-step Randomisation in the Pro-Diet feasibility RCT
An intervention to increase lycopene intake altered some circulating metabolites amongst men at increased risk of prostate cancer. In our lycopene intervention, pyruvate levels were decreased by 0.56 SD per unit increase in circulating lycopene, a change which our MR analysis suggests is associated with a 15% decrease in prostate cancer risk. This supports previously proposed metabolic pathway mechanisms for prostate cancer cells, where cells are unable to metabolise glucose rapidly and have to resort to an exogenous energy source, such as extracellular pyruvate, which may play a crucial role in tumour development (19, 20) .
Step 
Limitations/ Further work
There are limitations associated with this technique. One of the main limitations is the nature of feasibility trials, which cannot be designed to test effects of intervention on all intermediate biomarker levels. We cannot therefore discard other potential effects of the interventions which are not observed in the feasibility trial due to low power, that we may otherwise observe in a definitive, adequately powered trial (2) . Also important in this case is the 4 th IV assumption, where the observed effect of the intervention or treatment is a local average, that is, it may only apply to a specific subgroup of patients, and it may incorrectly translate at individual level or in a different subgroup, an issue that affects both RCTs and MR studies and may be seen in some clinical settings (21) (22) (23) (24) .
Using data from large GWAS studies, an adequately powered MR can be conducted, which provides confidence in the MR analysis results (25 the outcome, such as in the case of prediction models. In addition, a lack of evidence of a causal effect of the intermediate endpoint on the outcome also does not suggest that the intervention has no effect on the clinical outcome, rather it shows there is no causal effect via the presented pathway.
There are various peer-reviewed publications on the use of MR in epidemiology which provide more theoretical and methodological support with regards to conduction and understanding of MR (6, 8, 26) . Assessing the pathways through which the SNPs are likely to act and giving careful consideration on the methods employed are vital in order to correctly apply and interpret MR studies (27, 28) .
Issues such as having multiple biomarkers on separate pathways or multiple biomarkers on the same pathway, incorrectly assigning, defining and quantifying time-dependent exposures should be rigorously addressed and caution should be taken when interpreting and generalising findings (7, 27, 28) . More GWAS studies in the 'omics field would allow the identification of a wider variety of biomarkers and provide more robust associations which would increase the number and the reliability of using the two-step randomisation approach in feasibility RCTs. This technique could also be employed in other areas such as behavioural studies. For instance, we can use intermediate biomarkers from a smoking cessation intervention and use MR to assess the causal effect of these biomarkers on pertinent long-term clinical outcomes, such as lung cancer development or mortality.
The same technique could also be used in drug development by validating putative biomarker drug targets.
